132 related articles for article (PubMed ID: 18628356)
21. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.
Kim TY; Kim WB; Song JY; Rhee YS; Gong G; Cho YM; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2005 Nov; 63(5):588-93. PubMed ID: 16268813
[TBL] [Abstract][Full Text] [Related]
22. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes.
Oler G; Cerutti JM
Cancer; 2009 Mar; 115(5):972-80. PubMed ID: 19152441
[TBL] [Abstract][Full Text] [Related]
23. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.
Lee X; Gao M; Ji Y; Yu Y; Feng Y; Li Y; Zhang Y; Cheng W; Zhao W
Ann Surg Oncol; 2009 Feb; 16(2):240-5. PubMed ID: 19034577
[TBL] [Abstract][Full Text] [Related]
24. The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma.
Sedliarou I; Saenko V; Lantsov D; Rogounovitch T; Namba H; Abrosimov A; Lushnikov E; Kumagai A; Nakashima M; Meirmanov S; Mine M; Hayashi T; Yamashita S
Int J Oncol; 2004 Dec; 25(6):1729-35. PubMed ID: 15547711
[TBL] [Abstract][Full Text] [Related]
25. Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features.
Durand S; Ferraro-Peyret C; Joufre M; Chave A; Borson-Chazot F; Selmi-Ruby S; Rousset B
Endocr Relat Cancer; 2009 Jun; 16(2):467-81. PubMed ID: 19208736
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas.
Nakayama H; Yoshida A; Nakamura Y; Hayashi H; Miyagi Y; Wada N; Rino Y; Masuda M; Imada T
Anticancer Res; 2007; 27(5B):3645-9. PubMed ID: 17972530
[TBL] [Abstract][Full Text] [Related]
27. Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas.
Chuang TC; Chuang AY; Poeta L; Koch WM; Califano JA; Tufano RP
Head Neck; 2010 Feb; 32(2):229-34. PubMed ID: 19626635
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
[TBL] [Abstract][Full Text] [Related]
29. Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas.
McCarthy RP; Wang M; Jones TD; Strate RW; Cheng L
Clin Cancer Res; 2006 Apr; 12(8):2414-8. PubMed ID: 16638846
[TBL] [Abstract][Full Text] [Related]
30. Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature.
Rossi S; Fugazzola L; De Pasquale L; Braidotti P; Cirello V; Beck-Peccoz P; Bosari S; Bastagli A
Endocr Relat Cancer; 2005 Jun; 12(2):281-9. PubMed ID: 15947103
[TBL] [Abstract][Full Text] [Related]
31. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
[TBL] [Abstract][Full Text] [Related]
32. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma.
Sheu SY; Grabellus F; Schwertheim S; Handke S; Worm K; Schmid KW
Horm Metab Res; 2009 Jun; 41(6):482-7. PubMed ID: 19370505
[TBL] [Abstract][Full Text] [Related]
33. Loss of heterozygosity in 73 human thyroid tumors.
Wozniak A; Wiench M; Olejniczak A; Wloch J; Lachinski A; Lange D; Olczyk T; Jarzab B; Limon J
Neuro Endocrinol Lett; 2005 Oct; 26(5):521-5. PubMed ID: 16264407
[TBL] [Abstract][Full Text] [Related]
34. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid.
Jin L; Sebo TJ; Nakamura N; Qian X; Oliveira A; Majerus JA; Johnson MR; Lloyd RV
Diagn Mol Pathol; 2006 Sep; 15(3):136-43. PubMed ID: 16932068
[TBL] [Abstract][Full Text] [Related]
35. Progression of solitary and multifocal papillary thyroid carcinoma - a retrospective study of 368 patients.
Zheng XQ; Wang C; Xu M; Yu Y; Yun XW; Jia YS; Wei SF; Ren XB; Gao M
Chin Med J (Engl); 2012 Dec; 125(24):4434-9. PubMed ID: 23253715
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis.
Lee JH; Lee ES; Kim YS
Cancer; 2007 Jul; 110(1):38-46. PubMed ID: 17520704
[TBL] [Abstract][Full Text] [Related]
37. [BRAF V600E mutation in papillary thyroid carcinoma: prevalence and detection in fine needle aspiration specimens].
Dujardin F; Pagès JC; Collin C; de Calan L; Lecomte P; Guyétant S
Ann Pathol; 2010 Aug; 30(4):252-62. PubMed ID: 20837233
[TBL] [Abstract][Full Text] [Related]
38. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.
Yip L; Nikiforova MN; Carty SE; Yim JH; Stang MT; Tublin MJ; Lebeau SO; Hodak SP; Ogilvie JB; Nikiforov YE
Surgery; 2009 Dec; 146(6):1215-23. PubMed ID: 19958951
[TBL] [Abstract][Full Text] [Related]
39. [Expression of BRAF V600E mutation in different thyroid lesions].
Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
[TBL] [Abstract][Full Text] [Related]
40. [BRAF(T1799A) mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma].
Cañadas Garre M; López de la Torre Casares M; Becerra Massare P; López Nevot MÁ; Villar Del Moral J; Muñoz Pérez N; Vílchez Joya R; Montes Ramírez R; Llamas Elvira JM
Endocrinol Nutr; 2011 Apr; 58(4):175-84. PubMed ID: 21441079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
